Basel Medical Prices 6M-Unit Offering at $1.33 with Zero-Cash Warrants
BMGL is trading near its 52-week low of $3.88 (5.4% above the low) on light trading volume (0.1× avg).
Summary
Basel Medical Group priced its 6-million-unit offering at US$1.33 per unit, with warrants that could add up to 6 million more shares via zero-cash exercise. Net proceeds are estimated at US$7.37 million.
Key Events · Financing and Capital Events · BMGL
-
Offering Priced at $1.33 Per Unit
The 6,000,000-unit offering is priced at US$1.33 per unit, a substantial discount to the US$4.19 closing price on September 22, 2026. Each unit consists of one ordinary share (or pre-funded warrant) and one common warrant.
-
Zero-Cash Warrant Exercise Adds Dilution
Common warrants are exercisable at 110% of the offering price and include a zero-cash exercise option. If all warrants are exercised on a zero-cash basis, up to 6,000,000 additional ordinary shares would be issued with no additional cash proceeds to the company.
-
Net Proceeds Estimated at $7.37M
Assuming all units are sold, net proceeds are estimated at approximately US$7.37 million after a 6.0% placement agent fee (capped at US$400,000) and estimated offering expenses. Proceeds are earmarked for working capital, M&A, and general corporate purposes.
-
Placement Agent and Lock-Up Terms
Cathay Securities, Inc. is acting as sole placement agent on a best-efforts basis. The company, officers, directors, and certain shareholders are subject to 180-day lock-up agreements following the closing.
Analysis · BMGL · Industrial Applications And Services
Basel Medical Group has finalized terms for its previously announced 6-million-unit offering, pricing each unit at US$1.33 — a deep discount to the US$4.19 closing price on September 22, 2026. Each unit includes one ordinary share (or pre-funded warrant) and one common warrant exercisable at 110% of the offering price, with a zero-cash exercise option that could add up to 6 million additional shares without any cash proceeds to the company. The offering is expected to raise approximately US$7.37 million in net proceeds, which management intends to use for working capital, M&A, and general corporate purposes. The highly dilutive structure — combined with the company's recent reverse split, Nasdaq compliance history, and pending securities class action — makes this a critical capital event for existing shareholders.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.9% of the 1009 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BMGL was trading at $4.09 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $6.4M. The 52-week trading range was $3.88 to $25.80. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.